Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co.,Ltd. Fundamental Analysis
Rohto Pharmaceutical Co.,Ltd. (4527.T) shows moderate financial fundamentals with a PE ratio of 16.14, profit margin of 10.27%, and ROE of 12.66%. The company generates $335.8B in annual revenue with strong year-over-year growth of 13.95%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 62.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4527.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4527.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent4527.T trades at attractive valuation levels.
Growth Score
Moderate4527.T shows steady but slowing expansion.
Financial Health Score
Excellent4527.T maintains a strong and stable balance sheet.
Profitability Score
Weak4527.T struggles to sustain strong margins.
Key Financial Metrics
Is 4527.T Expensive or Cheap?
P/E Ratio
4527.T trades at 16.14 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 4527.T's PEG of -4.82 indicates potential undervaluation.
Price to Book
The market values Rohto Pharmaceutical Co.,Ltd. at 1.94 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.13 times EBITDA. This signals the market has high growth expectations.
How Well Does 4527.T Make Money?
Net Profit Margin
For every $100 in sales, Rohto Pharmaceutical Co.,Ltd. keeps $10.27 as profit after all expenses.
Operating Margin
Core operations generate 11.85 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.66 in profit for every $100 of shareholder equity.
ROA
Rohto Pharmaceutical Co.,Ltd. generates $7.48 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Rohto Pharmaceutical Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Rohto Pharmaceutical Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
4527.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.14
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-4.82
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.94
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.66
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.03
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How 4527.T Stacks Against Its Sector Peers
| Metric | 4527.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.14 | 22.36 | Better (Cheaper) |
| ROE | 12.66% | 1238.00% | Weak |
| Net Margin | 10.27% | -5096.00% (disorted) | Strong |
| Debt/Equity | 0.18 | 1.23 | Strong (Low Leverage) |
| Current Ratio | 2.03 | 2.47 | Strong Liquidity |
| ROA | 7.48% | -191998.00% (disorted) | Weak |
4527.T outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Rohto Pharmaceutical Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
64.03%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
101.44%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
94.13%
Industry Style: Defensive, Dividend, Low Volatility
High Growth